Δγ 134.5 herpes simplex viruses encoding human cytomegalovirus IRS1 or TRS1 induce interferon regulatory factor 3 phosphorylation and an interferon-stimulated gene response

Journal of Virology

Volumn 86, Issue 1, 2012, Pages 610-614

  Cassady, Kevin A ^a   Saunders, Ute ^a   Shimamura, Masako ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTERFERON; INTERFERON REGULATORY FACTOR 3;

ARTICLE; CHIMERA; CONTROLLED STUDY; CXCL10 GENE; GENE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENETIC CODE; HERPES SIMPLEX VIRUS; HUMAN CYTOMEGALOVIRUS; IFIT1 GENE; IRS1 GENE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRS1 GENE; VIRUS CELL INTERACTION; VIRUS GENE; VIRUS REPLICATION; WILD TYPE;

CELL LINE; CYTOMEGALOVIRUS; GENE EXPRESSION; GENETIC VECTORS; HERPES SIMPLEX; HUMANS; INTERFERON REGULATORY FACTOR-3; INTERFERON-BETA; ONCOLYTIC VIROTHERAPY; PHOSPHORYLATION; SIMPLEXVIRUS; VIRAL PROTEINS; VIRUS REPLICATION;

HUMAN HERPESVIRUS 5; SIMPLEXVIRUS;

EID: 84855932767     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.05099-11     Document Type: Article

References (43)

1. Andersen J, VanScoy S, Cheng TF, Gomez D, Reich NC. 2008. IRF-3-dependent and augmented target genes during viral infection. Genes Immun. 9:168 -175.
2. Andreansky S, et al. 1998. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther. 5:121-130.
3. Andrews NC, Faller DV. 1991. A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res. 19:2499.
4. Benencia F, et al. 2005. HSV oncolytic therapy upregulates interferoninducible chemokines and recruits immune effector cells in ovarian cancer. Mol. Ther. 12:789-802.
5. Benencia F, Courreges MC, Fraser NW, Coukos G. 2008. Herpes virus oncolytic therapy reverses tumor immune dysfunction and facilitates tumor antigen presentation. Cancer Biol. Ther. 7:1194 -1205.
6. Chelbi-Alix MK, Vidy A, El Bougrini J, Blondel D. 2006. Rabies viral mechanisms to escape the IFN system: the viral protein P interferes with IRF-3, Stat1, and PML nuclear bodies. J. Interferon Cytokine Res. 26: 271-280.
7. Chou J, Roizman B. 1992. The gamma 1(34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programmed cell death in neuronal cells. Proc. Natl. Acad. Sci. U. S. A. 89:3266 -3270.
8. Chou J, Roizman B. 1994. Herpes simplex virus 1 gamma(1)34.5 gene function, which blocks the host response to infection, maps in the homologous domain of the genes expressed during growth arrest andDNAdamage. Proc. Natl. Acad. Sci. U. S. A. 91:5247-5251.
9. Conrady CD, Halford WP, Carr DJ. 2011. Loss of the type I interferon pathway increases vulnerability of mice to genital herpes simplex virus 2 infection. J. Virol. 85:1625-1633.
10. Fulci G, et al. 2006. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc. Natl. Acad. Sci. U. S. A. 103: 12873-12878.
11. Hakki M, Marshall EE, De Niro KL, Geballe AP. 2006. Binding and nuclear relocalization of protein kinase R by human cytomegalovirus TRS1. J. Virol. 80:11817-11826.
12. Harrow S, et al. 2004. HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. Gene Ther. 11:1648 -1658.
13. He B, Chou J, Liebermann DA, Hoffman B, Roizman B. 1996. The carboxyl terminus of the murine MyD116 gene substitutes for the corresponding domain of the gamma(1)34.5 gene of herpes simplex virus to preclude the premature shutoff of total protein synthesis in infected human cells. J. Virol. 70:84 -90.
14. Honda K, Takaoka A, Taniguchi T. 2006. Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors. Immunity 25:349 -360.
15. Ikeda K, et al. 1999. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat. Med. 5:881- 887.
16. Kleinman ME, et al. 2008. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 452:591-597.
17. Kumar A, Zhang J, Yu FS. 2006. Toll-like receptor 3 agonist poly(I:C)-induced antiviral response in human corneal epithelial cells. Immunology 117:11-21.
18. Leib DA, et al. 1999. Interferons regulate the phenotype of wild-type and mutant herpes simplex viruses in vivo. J. Exp. Med. 189:663- 672.
19. Li H, et al. 2006. Herpes simplex virus 1 infection induces the expression of proinflammatory cytokines, interferons and TLR7 in human corneal epithelial cells. Immunology 117:167-176.
20. Markert JM, et al. 2009. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre- and post-tumor resection for recurrent GBM. Mol. Ther. 17:199 -207.
21. Markert JM, et al. 2000. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther. 7:867- 874.
22. Masatani T, et al. 2010. Rabies virus nucleoprotein functions to evade activation of the RIG-I-mediated antiviral response. J. Virol. 84: 4002-4012.
23. McAllister CS, Samuel CE. 2009. The RNA-activated protein kinase enhances the induction of interferon-beta and apoptosis mediated by cytoplasmic RNA sensors. J. Biol. Chem. 284:1644 -1651.
24. Menachery VD, Pasieka TJ, Leib DA. 2010. Interferon regulatory factor 3-dependent pathways are critical for control of herpes simplex virus type 1 central nervous system infection. J. Virol. 84:9685-9694.
25. Miller CG, Fraser NW. 2003. Requirement of an integrated immune response for successful neuroattenuated HSV-1 therapy in an intracranial metastatic melanoma model. Mol. Ther. 7:741-747.
26. Miller CG, Fraser NW. 2000. Role of the immune response during neuroattenuated herpes simplex virus-mediated tumor destruction in a murine intracranial melanoma model. Cancer Res. 60:5714 -5722.
27. Mohr I, et al. 2001. A herpes simplex virus type 1 gamma34.5 secondsite suppressor mutant that exhibits enhanced growth in cultured glioblastoma cells is severely attenuated in animals. J. Virol. 75: 5189 -5196.
28. Nakayama Y, et al. 2010. Role of PKR and type I IFNs in viral control during primary and secondary infection. PLoS Pathog. 6:e1000966.
29. Paladino P, Mossman KL. 2009. Mechanisms employed by herpes simplex virus 1 to inhibit the interferon response. J. Interferon Cytokine Res. 29:599-607.
30. Parker JN, et al. 2000. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc. Natl. Acad. Sci. U. S. A. 97:2208 -2213.
31. Pasieka TJ, et al. 2009. Host responses to wild-type and attenuated herpes simplex virus infection in the absence of Stat1. J. Virol. 83:2075-2087.
32. Pérez de Diego R, et al. 2010. Human TRAF3 adaptor molecule deficiency leads to impaired Toll-like receptor 3 response and susceptibility to herpes simplex encephalitis. Immunity 33:400-411.
33. Rampling R, et al. 2000. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther. 7:859-866.
34. Samuel CE. 2001. Antiviral actions of interferons. Clin. Microbiol. Rev. 14:778-809.
35. Samuel MA, et al. 2006. PKR and RNase L contribute to protection against lethal West Nile Virus infection by controlling early viral spread in the periphery and replication in neurons. J. Virol. 80:7009 -7019.
36. Shah AC, et al. 2007. Enhanced antiglioma activity of chimeric HCMV/ HSV-1 oncolytic viruses. Gene Ther. 14:1045-1054.
37. Streck CJ, et al. 2004. Restriction of neuroblastoma angiogenesis and growth by interferon-alpha/beta. Surgery 136:183-189.
38. Talon J, et al. 2000. Activation of interferon regulatory factor 3 is inhibited by the influenza A virus NS1 protein. J. Virol. 74:7989 -7996.
39. Ueta M, Hamuro J, Kiyono H, Kinoshita S. 2005. Triggering of TLR3 by polyI:C in human corneal epithelial cells to induce inflammatory cytokines. Biochem. Biophys. Res. Commun. 331:285-294.
40. Verpooten D, Ma Y, Hou S, Yan Z, He B. 2009. Control of TANKbinding kinase 1-mediated signaling by the gamma(1)34.5 protein of herpes simplex virus 1. J. Biol. Chem. 284:1097-1105.
41. Vollstedt S, et al. 2004. Interplay between alpha/beta and gamma interferons with B, T, and natural killer cells in the defense against herpes simplex virus type 1. J. Virol. 78:3846 -3850.
42. Wakimoto H, Johnson PR, Knipe DM, Chiocca EA. 2003. Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells. Gene Ther. 10:983-990.
43. Zhang P, Samuel CE. 2008. Induction of protein kinase PKR-dependent activation of interferon regulatory factor 3 by vaccinia virus occurs through adapter IPS-1 signaling. J. Biol. Chem. 283:34580 -34587.